Search results
Results from the WOW.Com Content Network
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. [9] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin . [ 9 ]
New TYSABRI ® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity - Earlier Treatment with TYSABRI Demonstrated Reduction in Relapse Severity ...
These seven patients were being treated for varying neurodegenerative disorders including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS-P), Parkinson's, spinal cord injury, traumatic brain injury, and stroke. A total of 113 injections were performed on the 31 patients, with one patient having ...
First, it produces uric acid after ingestion, [55] which is a natural antioxidant; [56] second, it has been shown to induce axonal rewiring in laboratory animals with stroke, [57] and spinal cord injury. [58] However it can cause health problems in a long-term treatment, [59] mainly kidney stones. [60]
Multiple sclerosis drug Tysabri is arguably the most important drug to both Biogen Idec (NAS: BIIB) and Elan (NYS: ELN) . It makes up essentially all Elan's sales after selling its drug- delivery ...
Tysabri: mab: humanized: ... recovery of motor function after stroke Regavirumab: mab: human: cytomegalovirus glycoprotein B: cytomegalovirus infection Regdanvimab [29]
Routes of administration are usually classified by application location (or exposition). The route or course the active substance takes from application location to the location where it has its target effect is usually rather a matter of pharmacokinetics (concerning the processes of uptake, distribution, and elimination of drugs).
Stroke is the 5th-leading cause of death in the U.S. and a leading cause of severe disability. On average, a person dies from stroke every 4 minutes. He was given hours to live after stroke. 17 ...